Immunogenicity of ALVAC-HIV vCP1521 in infants of of HIV-1 infected women in Uganda (HPTN 027): The first pediatric HIV vaccine trial in Africa

Authors

Pontiano Kaleebu, Uganda Virus Research Institute, Entebbe, Uganda
Harr Freeya Njai, Uganda Virus Research Institute, Entebbe, Uganda
Lei Wang, Fred Hutchinson Cancer Research Center, Seattle, WA
Norman Jones, Viral and Rickettsial Disease Laboratory, Richmond, CA
Isaac Ssewanyana, Joint Clinical Research Center, Kampala, Uganda
Paul Richardson, Johns Hopkins UniversityFollow
Kenneth Kintu, Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda
Lynda Emel, Fred Hutchinson Cancer Research Center, Seattle, WA
Philippa Musoke, Makerere University, Kampala, Uganda
Mary Glenn Fowler, Johns Hopkins University
San-San Ou, Fred Hutchinson Cancer Research Center, Seattle, WA
J. Brooks Jackson, Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda
Laura Guay, George Washington UniversityFollow
Philip Andrew, FHI 360, Durham, NC
Lynn Baglyos, Sanofi Pasteur, Swiftwater, PA
Huyen Cao, Viral and Rickettsial Disease Laboratory, Richmond, CA

Document Type

Journal Article

Publication Date

3-1-2014

Journal

Journal of Acquired Immune Deficiency Syndromes

Volume

Volume 65, Issue 3

Inclusive Pages

268-277

Keywords

AIDS Vaccines--adverse effects; AIDS Vaccines--immunology; HIV Infections--prevention & control; HIV-1--immunology; Infectious Disease Transmission, Vertial--prevention & control; Vaccination--adverse effects; Vaccination--methods

APA Citation

Kaleebu, P., Njai, H.F., Wang, L., Jones, N., Ssewanyana, I. et al. (2014). Immunogenicity of ALVAC-HIV vCP1521 in infants of of HIV-1 infected women in Uganda (HPTN 027): The first pediatric HIV vaccine trial in Africa. Journal of Acquired Immune Deficiency Syndromes, 65(3), 268-277.

Peer Reviewed

1